http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100432953-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10032 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
| filingDate | 2001-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100432953-B1 |
| titleOfInvention | Recombinant Adenovirus with Enhanced Tumoricidal Effect |
| abstract | The present invention relates to an adenovirus and a pharmaceutical anti-tumor composition comprising the same, which exhibit an improved tumor killing effect, and more particularly, tumor cell necrosis by causing mutations in the ElB 19 gene so that expression of the adenovirus ElB 19 gene is suppressed. And it relates to a recombinant adenovirus and a pharmaceutical anti-tumor composition comprising the same by inducing apoptosis at the same time, the tumor cell killing effect, the recombinant adenovirus of the present invention induces cell necrosis and cell death in infected cells simultaneously to kill tumor cells The ability to greatly improve the ability to overcome the limitations of the conventional method for treating tumors by recombinant adenovirus, moreover, the pharmaceutical composition of the present invention is used in combination with the conventional cancer treatment method, in particular cancer treatment method that induces cell death In case of maximum therapeutic effect Can. |
| priorityDate | 2001-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 357.